Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823443 · ClinicalTrials.gov registry record
COPD Exacerbation Blood and Urine Biomarkers Study
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 7
- Enrollment target
NCT03823443: Clinical Trial study, sponsored by Columbia University.
NCT03823443 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03823443 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.
Primary Outcome
Serum levels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2021-01-08 |
Why NCT03823443 stopped before completion
NCT03823443 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03823443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03823443 about?
NCT03823443 is a clinical study titled "COPD Exacerbation Blood and Urine Biomarkers Study". This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be ass...
What is the current status of trial NCT03823443?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2018-06-07. Estimated completion is 2021-01-08.
Who is sponsoring clinical trial NCT03823443?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI